Uncomplicated Urinary Tract Infection Market to Register Stupendous Growth During the Forecast Period (2022-32) | Key Players – Fimbrion Therapeutics, Iterum Therapeutics, Inmunotek, Janssen
Moreover, the rise in healthcare spending across the world, and the increase in Urinary tract infection cases, mainly due to lifestyle changes, will also stimulate the Uncomplicated Urinary Tract Infection Market growth in the coming years.
DelveInsight’s “Uncomplicated Urinary Tract Infection Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Uncomplicated Urinary Tract Infection market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Uncomplicated Urinary Tract Infection market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Uncomplicated Urinary Tract Infection: An Overview
Uncomplicated urinary tract infections typically affect individuals who are otherwise healthy and have no structural or neurological urinary tract abnormalities. Complicated urinary tract infection is associated with factors compromising the urinary tract or host defense.
Antibiotics are still considered the gold standard of urinary tract infection treatments. The antimicrobial agents most commonly used to treat uncomplicated urinary tract infections include the combination drug trimethoprim and sulfamethoxazole (TMP-SMX), trimethoprim, β-lactams, fluoroquinolones, nitrofurantoin, and fosfomycin tromethamine. Oral treatment with fosfomycin trometamol and nitrofurantoin (e.g., nitrofurantoin monohydrate/macrocrystals) along with TMP-SMX is considered the first-line treatment. In female patients with mild to moderate symptoms, symptomatic therapy (e.g., Ibuprofen) may be considered in consultation with individual patients as an alternative to antimicrobial treatment.
Uncomplicated Urinary Tract Infection Market Key Facts
-
In the year 2021, total diagnosed cases of Uncomplicated Urinary Tract Infection was 19,600+ in the 7MM, which is expected to grow during the study period, i.e., 2019–2032.
-
In 2021, the total market size of Uncomplicated Urinary Tract Infections was USD 927 million, which is expected to rise by 2032.
-
The total market size of Uncomplicated Urinary Tract Infections in the United States was USD 590 million in 2021.
-
In EU5, the total market size of Uncomplicated Urinary Tract Infection was USD 228 million in 2021.
-
Among the 7MM, the highest number of age-specific uncomplicated urinary tract infection cases was observed in the US.
-
According to a study by Butler et al. (2015), in England, 37% of females surveyed reported a urinary tract infection at some point in their lifetime, and 28% reported more than one infection episode.
Uncomplicated Urinary Tract Infection Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Uncomplicated Urinary Tract Infection market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Uncomplicated Urinary Tract Infection market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Uncomplicated Urinary Tract Infection Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
The Report Covers the Uncomplicated Urinary Tract Infection Epidemiology Segmented, by –
-
Total Pathogen-specific Cases of Uncomplicated Urinary Tract Infection
-
Total Age-specific Cases of Uncomplicated Urinary Tract Infection
-
Total Occurrence-specific Cases of Uncomplicated Urinary Tract Infection
-
Total Diagnosed Cases of Uncomplicated Urinary Tract Infection
-
Total Treated Cases (across lines) of Uncomplicated Urinary Tract Infection
Uncomplicated Urinary Tract Infection Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Uncomplicated Urinary Tract Infection market or expected to get launched during the study period. The analysis covers the Uncomplicated Urinary Tract Infection market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Uncomplicated Urinary Tract Infection Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How Uncomplicated Urinary Tract Infection Market Will Evolve by 2032 @
https://www.delveinsight.com/sample-request/uncomplicated-urinary-tract-infection-market
Key companies involved in developing drugs for Uncomplicated Urinary Tract Infections include:
-
Fimbrion Therapeutics
-
Iterum Therapeutics
-
Inmunotek
-
Janssen Pharmaceuticals
-
Utility Therapeutics
-
GlaxoSmithKline
And many others
Uncomplicated Urinary Tract Infection Therapies covered in the report include:
-
Gepotidacin (GSK2140944)
-
GSK3882347
-
Sulopenem
-
Uromune (MV140)
-
Pivmecillinam
-
ExPEC Vaccine (ExPEC10V and ExPEC4V)
And many more
The emerging therapies which are under development will provide efficient therapeutic approaches with novel mechanisms of action for the treatment of patients affected with uncomplicated urinary tract infections.
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More @
https://www.delveinsight.com/sample-request/uncomplicated-urinary-tract-infection-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Uncomplicated Urinary Tract Infection Competitive Intelligence Analysis
4. Uncomplicated Urinary Tract Infection Market Overview at a Glance
5. Uncomplicated Urinary Tract Infection Disease Background and Overview
6. Uncomplicated Urinary Tract Infection Patient Journey
7. Uncomplicated Urinary Tract Infection Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Uncomplicated Urinary Tract Infection Treatment Algorithm, Current Treatment, and Medical Practices
9. Uncomplicated Urinary Tract Infection Unmet Needs
10. Key Endpoints of Uncomplicated Urinary Tract Infection Treatment
11. Uncomplicated Urinary Tract Infection Marketed Products
12. Uncomplicated Urinary Tract Infection Emerging Drugs and Latest Therapeutic Advances
13. Uncomplicated Urinary Tract Infection Seven Major Market Analysis
14. Attribute Analysis
15. Uncomplicated Urinary Tract Infection Market Outlook (In US, EU5, and Japan)
16. Uncomplicated Urinary Tract Infection Access and Reimbursement Overview
17. KOL Views on the Uncomplicated Urinary Tract Infection Market
18. Uncomplicated Urinary Tract Infection Market Drivers
19. Uncomplicated Urinary Tract Infection Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/uncomplicated-urinary-tract-infection-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
Uncomplicated Urinary Tract Infections Pipeline Insight
“Uncomplicated Urinary Tract Infections Pipeline Insights, 2022” report by DelveInsight outlays comprehensive insights into the present clinical/non-clinical development activities and growth prospects across the Uncomplicated Urinary Tract Infections Market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
 | Key Players – Fimbrion Therapeutics, Iterum Therapeutics, Inmunotek, Janssen){kind=link}